Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

2010398 citationsJournal Article

Authors

Roger R. Dmochowski · Vanderbilt University

Christopher R. Chapple · Royal Hallamshire Hospital

Victor W. Νitti · New York University

Michael B. Chancellor · Beaumont Hospital, Royal Oak

Karel Everaert · Ghent University

Catherine Thompson · Allergan (United Kingdom)

Grace Daniell

Abstract

OnabotulinumtoxinA at doses of 100 U or greater demonstrated durable efficacy in the management of idiopathic overactive bladder and urinary urgency incontinence. A dose of 100 U may be the dose that appropriately balances the symptom benefits with the post-void residual urine volume related safety profile.

Topics & Keywords

Urinary Bladder and Prostate Research Pelvic floor disorders treatments Gastrointestinal motility and disorders

Publication Details

Published in: The Journal of Urology

Volume 184, Issue 6, pp. 2416-2422

DOI: 10.1016/j.juro.2010.08.021

Field-Weighted Citation Impact: 34.67

Command Palette

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

Authors

Abstract

Topics & Keywords

Publication Details